Key facts
- Notable investors include Dingfeng Asset Management, Xingkong Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Increland
- ·The full record, as it builds
Funding rounds
No funding rounds for Increland are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Increland
Developer of innovative pharmaceutical products focused on the discovery and development of novel drug molecules designed to address unmet clinical needs. The company operates an integrated new drug discovery platform encompassing molecular biology, cell biology, pharmacology, toxicology, medicinal chemistry, and translational medicine. Through its comprehensive R&D capabilities and experienced drug development team, the company advances promising therapeutic candidates from early discovery to clinical development, enabling the delivery of innovative treatment solutions for patients across various disease areas.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2020
- Website
- cdincreland.com/
- Ownership
- Privately Held (backing)
Increland doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Increland shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Increland in its N-PORT filings yet. We sweep new filings monthly.